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The human immune system and the microbiota co-evolve, and their balanced
relationship is based on crosstalk between the two systems through the course of life.
This tight association and the overall composition and richness of the microbiota play an
important role in the modulation of host immunity and may impact the immune response
to vaccination. The availability of innovative technologies, such as next-generation
sequencing (NGS) and correlated bioinformatics tools, allows a deeper investigation
of the crosstalk between the microbiota and human immune responses. This review
discusses the current knowledge on the influence of the microbiota on the immune
response to vaccination and novel tools to deeply analyze the impact of the microbiome
on vaccine responses.
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INTRODUCTION
The term “human microbiota” refers to the complex communities of trillion symbiotic microbial
cells including bacteria, archea, viruses and fungi harbored by each individual. The number of
bacteria in the body is approximately of the same order as the number of human eukaryotic
cells, as recently revised by the study of Sender’s group (Sender et al., 2016). The majority
of them colonize the intestinal tract (gut microbiota), but microorganisms are present also
in other areas including the skin, the airways, and the genitourinary tract. The term “human
microbiome” generally refers to the collective genes harbored by these microbial cells. In the human
gut, the microbiome includes about 3 million unique genes mostly from bacteria (Turnbaugh
et al., 2007). These bacterial communities play a critical role in several body functions such
as food digestion, synthesis of essential vitamins, and protection against pathogenic invaders
(Kho and Lal, 2018).
The composition of the microbiota can be modulated by several factors throughout the
course of life, and it is particularly unstable in the first 2 years (Tamburini et al., 2016).
Factors such as gestational age, mode of delivery, diet, antibiotics exposure, probiotics and
nutritional supplements use, hygiene conditions host genetics as well as the interaction with
the immune system influence the composition of the microbiota. The first years of life is the
phase when the early microbiota can shape the immune system and vice versa. During this
period, commonly defined as “critical window,” the instability of the microbiota probably reflects
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the plasticity of the immune system in this time-limited period
that permits the high variability of the microbial composition.
Microbial imbalance, a state called “dysbiosis,” can predispose
the body to disease (Shreiner et al., 2015; Kho and Lal, 2018).
Many studies have highlighted the role of the gut microbiota in
inflammatory bowel diseases (IBDs) (Machiels et al., 2014; Zuo
and Ng, 2018), Clostridium difficile infection (Theriot et al., 2014),
metabolic and neuropsychiatric disorders (Kho and Lal, 2018),
rheumatoid arthritis, and other autoimmune diseases (Altmann
et al., 2018) and of non-gut microbiota in diseases such as
cystic fibrosis, chronic rhinosinusitis, periodontal, and chronic
obstructive pulmonary disease and recently in central nervous
system disorders (Wang and Kasper, 2014). The widely used
concept of “dysbiosis” is, however, challenging in its definition
because the known intra-variability and inter-variability of
the human microbiota make difficult the distinctions between
normal and abnormal microbial communities (Hooks and
O’Malley, 2017). The knowledge of the dynamics underlying
the interactions between the microbiota and the immune
system is important for understanding the potential implications
for human health.
In recent years, it has been shown that the microbiota can
also influence the immune response to vaccination (Jamieson,
2015; Zimmermann and Curtis, 2018b) and that microbial
alteration can impact the immune response to injectable and
oral vaccines (Lynn et al., 2018). Human immune response and
the microbial community develop in concert during the first
months of life when the majority of vaccinations are given.
For this reason, the composition of the early microbiota could
potentially play an important role in the responses to vaccines.
Evidence that the microbiota can influence vaccine responses
comes from both pre-clinical and clinical studies (Table 1). With
the use of germ-free (GF) or antibiotic-treated animals, impaired
antibody responses to influenza vaccine have been observed, thus
providing a demonstration of an effect of the microbiome on
vaccination (Oh et al., 2014). In humans, Actinobacteria were
shown to positively correlate with adaptive immune responses
to systemic [Bacillus Calmette–Guérin (BCG), tetanus toxoid
(TT), and hepatitis B virus (HBV)] and oral (polio) vaccination
in Bangladeshi infants, whereas higher levels of Enterobacter
were negatively associated (Huda et al., 2014). Other studies
focused on the rotavirus vaccine (RVV) immune response
confirmed a correlation between the infant gut microbiota
composition and the vaccine responses (Harris et al., 2017;
Harris V. et al., 2018).
In this review, we discuss the interactions of the bacterial
microbiota with the human immune system during the course
of the life, with a particular focus on the potential role exerted on
the immune response to vaccination.
THE HUMAN GUT MICROBIOTA
The gastrointestinal tract is a dynamic and semipermeable
multilayer ecosystem, where different players crosstalk, forming
a functional unit. Over 70% of the human microbiota lives in
the gastrointestinal tract in a mutually beneficial relationship
with its host. The gut microbiota is composed of 1013 to 1014
bacteria per gram of wet content, and it is characterized by a
gradient in bacteria concentration steadily increasing from the
gastric lumen to the small intestine up to the colon–rectum,
where it reaches its maximum concentration (Ursell et al., 2012).
Early gut colonizers include commensal facultative anaerobes
such as Enterobacter and Enterococci followed by an increased
relative abundance of strict anaerobes including Bifidobacterium,
Bacteroides, and Clostridium (Matamoros et al., 2013; Hugon
et al., 2015). The gut microbiota is dominated by the bacteria
phyla Firmicutes and Bacteroidetes and to a lesser extent by
Proteobacteria, Actinobacteria, and Verrucomicrobia (Bäckhed
et al., 2012). Bacterial localization along the gastrointestinal tract
is strongly influenced by nutrient distribution. Proteobacteria
and Lactobacillales are present in the small intestine because
monosaccharides, disaccharides, and amino acids present in
this sector represent their main growth factors. Beyond the
ileocecal valve, the microbial community changes, because
most of the carbohydrates available are polysaccharides that
Proteobacteria are not able to digest and use as a source of
energy whereas Bacteroides and Clostridiales have enzymes that
cut undigested polysaccharides. These fermentation processes
produce acetate, propionate (Bacteroidetes), and butyrate
(Firmicutes) that play an important role in maintaining a
healthy gut. The microbial community also shows substantive
differences between mucosal to lumen surfaces (Thursby and
Juge, 2017): Enterobacteriaceae and Bacteroides, Bifidobacterium,
Streptococcus, Enterococcus, Clostridium, Lactobacillus, and
Ruminococcus genera are predominant in the luminal surface
and can be identified in stool, whereas Clostridium, Lactobacillus,
Enterococcus, and Akkermansia are the predominant genera
detected in the mucus layer and epithelial crypts of the small
intestine (Swidsinski et al., 2005).
Recent advances in culture-independent approaches and
new techniques for viral enrichments from complex microbial
samples have increased the knowledge on another important
component of the microbiota, the “virobiota” and its genetic
content (virome) (Virgin, 2014). Both eukaryotic viruses and
bacteriophages are present in many host sites such as the
intestine, oral cavity, urinary tract, and skin. The most
abundant viruses associated with healthy human tissues are
bacteriophages, including both lysogenic prophages and lytic
phages that can establish a nonpathogenic relationship with
the human host (Dalmasso et al., 2014). Populations of
eukaryotic viruses in humans are heterogeneous, with distinct
groups of viruses predominating in different tissues. Viruses
in the gut mainly belong to the families Picornaviridae,
Reoviridae, Caliciviridae, and Astroviridae, but members of the
Adenoviridae, Picobirnaviridae, Herpesviridae, and Retroviridae
families can also be found (Duerkop and Hooper, 2013). The
lack of exhaustive information on virome underscores the
need to dedicate more efforts to its characterization and to
expand our knowledge of bacteriophages and their role in
shaping host immunity.
The characterization of the interactions between the
complex microbial community and the host is fundamental
for understanding the role that the microbiota plays in
health and disease, and potentially on the immune response
to vaccination.
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TABLE 1 | Correlations between microbiota and immune response to vaccination.
Vaccinea Host Major findings References
Meningococcal serogroup B
and C vaccines, the 13-valent
pneumococcal conjugate
vaccine; the hexavalent
combination vaccineb, BCG
Infant mice Antibiotic-driven dysbiosis leads to impaired antibody responses to
vaccination
Lynn et al., 2018
TIV OPV Mice Correlation between early expression of TLR5 and the magnitude of
the antibody response. Vaccine antibody responses in GF or
antibiotic-treated mice were impaired but restored by oral
reconstitution with a flagellated strain of E. coli
Oh et al., 2014
Live attenuated oral Shigella
dysenteriae 1 vaccine
NHP (cynomolgus
macaques)
The high level of diversity in the intestinal microbiota of macaques
correlates with improved protection upon vaccination
Seekatz et al., 2013
Live cholera strain CVD
103-HgR
Children from low-income
and high-income countries
Small bowel bacterial overgrowth (SBBO) could blunt the immune
response to CVD 103-HgR
Levine, 2010
Live attenuated oral Rotavirus
vaccine
Healthy Ghanaian infants,
RVV vaccinated
Intestinal microbiome composition correlates with RVV
immunogenicity and may contribute to the diminished RVV
immunogenicity observed in developing countries
Harris et al., 2017
Indian infants No significant differences in overall microbial community between
responder and not-responder infants to RV vaccination. A Modest
inhibitory effect of co-administered OPV on the first dose of RV was
observed
Parker et al., 2018
Pakistan infants RV response correlated with a higher relative abundance of bacteria
belonging to Clostridium cluster XI and Proteobacteria, including
bacteria related to Serratia and E. coli
Harris V. et al., 2018
Live attenuated oral Salmonella
typhi Ty21a vaccine
Adult healthy volunteers Differences in microbial composition or temporal stability observed
among individuals displaying multiphasic cellular responses and not
among individual able to mount a positive humoral response
Eloe-Fadrosh et al., 2013
OPV, BCG, TT, HBV Bangladesh infants High relative abundance of Actinobacteria, particularly of
Bifidobacterium, can enhance responses to both oral and
parenteral vaccines in infancy. Vaccine responsiveness can be
improved by promoting intestinal Bifidobacteria and minimizing
dysbiosis in infancy
Huda et al., 2014
a Inactivated influenza vaccine (TIV); oral polio virus (OPV); Bacillus Calmette–Guérin (BCG); tetanus toxoid (TT); and hepatitis B virus (HBV). bAgainst hepatitis B, diphtheria,
tetanus, pertussis, Haemophilus influenzae type b, poliomyelitis virus.
THE CROSSTALK BETWEEN
MICROBIOTA AND IMMUNE SYSTEM
The continuous and balanced interplay between the microbial
flora and the host is essential to preserve the body’s normal
functions. The immune system plays a critical role in maintaining
homeostasis with resident microbial communities ensuring a
mutualistic relationship. At the same time, the microbiota shapes
the immune system during the early life and thereafter continues
to modulate immunologic functions that are critical for the
host physiology.
In the absence of microbial stimulation, the intestinal
immune system is largely underdeveloped, both anatomically
and functionally (McDermott and Huffnagle, 2014). For
example, GF mice have a small number of intraepithelial
lymphocytes and an inappropriate balance of helper T-cell
subsets, with reduced production of immunoglobulin A (IgA)
and antimicrobial peptides (AMPs). Other anatomic alterations
are also present, such as immature mesenteric lymph nodes
and less active Peyer’s patches (PPs) with small germinal zones,
reduced mucus thickness with altered properties, elongation
of the villi structures with atrophy of crypts, and defective
angiogenesis. All these alterations are postulated to result from
the lack of microbiota-derived signals as shown by the re-
establishment of the normal organization of the intestinal
immune system upon microbial stimulation (Sommer and
Bäckhed, 2013). Moreover, murine neonatal T cells are skewed
toward a Th2 phenotype, which exerts suppressive effects on
Th1 cell-mediated immunity, thus allowing microbial homing
and limiting potentially harmful pro-inflammatory responses
(Adkins and Du, 1998). Also in humans, it has been shown
that neonatal naïve CD4+ T cells have an intrinsic preference
to differentiate into Th2 cells (Hebel et al., 2014). Various
regulatory cells are also involved in the control of the immune
homeostasis in order to tolerate the microbial colonization
at mucosal sites at birth. In contrast, a state of dysbiosis
promotes a strong Th1 displacement and an inflammatory
state that can be involved in some diseases in adulthood
(Tamburini et al., 2016).
As schematically represented in Figure 1, the main interface
between the host and microorganisms is represented by the
intestinal epithelial cells (IECs); the microbiota communicates
with the IECs through microbe-associated molecular patterns
(MAMPs) and metabolic products. On the other hand, IECs
are provided with specialized surface structures (microvilli, cilia,
mucus production, and intercellular junctions) and a set of innate
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FIGURE 1 | Interactions between the microbial community and the immune system at mucosal surfaces. Interactions between microbiota and host cells occur
mainly at the intestinal epithelium surface, which constitutes the principal physical and chemical barriers for maintaining intestinal immune homeostasis. The gut
microbiota is separated from the intestinal epithelium by a layer of mucus secreted by goblet cells (GCs). Microbe-associated molecular patterns (MAMPs),
expressed on the bacterial surface, are recognized by pattern recognition receptors (PRRs), expressed by intestinal epithelial cells (IECs), and induce a variety of
effects to block bacteria such as the production of the antimicrobial peptides (AMPs). IEC-released factors, such as retinoic acid (RA) and TGF-β, promote the
development in the lamina propria of tolerogenic DCs that stimulate the differentiation of T cells into Treg. B cells differentiate into plasma cells (PCs) secreting IgA
that translocate through the epithelium and are released into the mucus layer where control bacteria adhesion to host tissues. Macrophages, stimulated by signals
such as flagellin, release IL-23, which in turn promotes the production of IL-22 by ILC3. IL-22 stimulates the release of RegIIIγ, an antimicrobial peptide produced by
IECs. ILC2 contributes to the control of mucus by secreting IL-13, a cytokine that drives the differentiation of intestinal epithelial stem cells toward GC, which in turn
produce mucin glycoproteins.
immune receptors, named pattern recognition receptors (PRRs),
which recognize the MAMPs (Belkaid and Hand, 2014). PRRs,
classified into toll-like receptors (TLRs), NOD-like receptors
(NLRs), and retinoic acid-inducible gene I (RIG-I)-like receptors
(RLRs) (Kamada et al., 2013), recognize microbial structures such
as lipopolysaccharide (LPS) (TLR4), flagellin (TLR5 and NLRC4),
lipoteichoic acid, bacterial lipoproteins, and peptidoglycan of
Gram-positive bacteria (TLR2, Nod1, and Nod2).
The immune system mounts a series of innate and
adaptive immune mechanisms aimed at reinforcing microbiota
containment, barrier immunity, and tissue repair in a manner
uncoupled from inflammation. Tolerance of the normal gut
microbiota is a crucial element of intestinal homeostasis,
requiring an extensive network of regulatory immune cells
including T regulatory (Tregs) and tolerogenic dendritic cells
(DC) (Belkaid and Harrison, 2017). Sensing of commensal
microbiota through the TLR-MyD88 signaling pathway is
a strategy applied by the immune system for maintaining
host–microbial homeostasis (Rakoff-Nahoum and Medzhitov,
2007). For example, the surface polysaccharide A (PSA) produced
by Bacteroides fragilis and recognized by the TLR2 mediates
conversion of CD4+ T cells into Foxp3+ IL-10-producing Treg
cells, promoting the immunologic tolerance in the gut (Round
et al., 2011). Also, Clostridia species, especially Clostridium
cluster IV (C. leptum group) and XIVa (C. coccoides group),
are implicated in the development of local and systemic IL-10-
expressing Foxp3+ Treg cells and the production of transforming
growth factor-β1 in the large intestine (Atarashi et al., 2011). The
expression of PRRs varies considerably in the different tracts of
the gut as well as the composition of the resident microbiota.
As a result, crosstalk between the microbiota and the immune
system is different in the colon compared with the small intestine
(Schuijt et al., 2013).
Furthermore, IECs release factors, such as retinoic acid
and TGF-β, that promote the development in the lamina
propria of antigen-presenting cells (APCs), both DCs and
macrophages, with tolerogenic properties (Figure 1). APCs
stimulated by signals, such as flagellin, release IL-23 that in
turn promotes the expression of IL-22 by innate lymphocyte
cells type 3 (ILC3). IL-22 stimulates the production of
RegIIIγ, an AMP produced by IECs, which is retained in
the mucus layer (Kinnebrew et al., 2012). ILC2 indirectly
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control microbiota colonization by secreting IL-13, a cytokine
that drives the differentiation of intestinal epithelial stem cells
toward goblet cells, which in turn produce mucin glycoproteins
(Britanova and Diefenbach, 2017; Figure 1). These antimicrobial
mechanisms are constitutively engaged by the immune system to
prevent overgrowth of the colonizing microbes and monitoring
the resident microbiota through a process called immune
homeostasis (Abraham and Medzhitov, 2011).
IgA production is also influenced by the gut microbiota;
indeed, the number of IgA-producing cells in the intestine
is markedly decreased in GF mice (Fagarasan et al., 2010).
The dominant inductive site for IgA B-cell responses in
GALT are the PPs, in which the formation of GC plays a
critical role for the development of affinity matured IgA B
cells and the formation of long-lived plasma and memory B
cells. Contrary to other inductive sites, the PPs consistently
exhibit GC owing to the presence of the microbiota and
of food antigens in the lumen. There are several factors
that promote the IgA isotype switching, such as TGF-β,
the proliferation-inducing ligand (APRIL), or B-cell activating
factor (BAFF). In addition, nitrogen oxide produced by iNOS-
expressing cells can promote IgA differentiation, possibly via
regulation of TGF-β receptor II expression on B cells (Tezuka
et al., 2011). Within the intestinal lamina propria, B cells
secrete soluble IgA, which are subsequently transcytosed across
epithelial cells, thereby controlling host–commensal interaction
by binding to luminal microorganisms, thus preventing their
translocation across the epithelial barrier (stratification) and
preserving its integrity and functionality (Mathias et al., 2014).
Beyond their well-known role in pathogen neutralization and
clearance (Cerutti et al., 2011), SIgA selectively retro-transports
bound antigens back into intestinal Peyer’s patches where
immune complexes associate with DC resulting in the onset of
immunomodulatory types of responses (Corthésy, 2013). IgA-
deficient mice indeed show increased microbiota penetration of
the intestinal barrier and elevated microbe-specific serum IgG
(Suzuki et al., 2004; Figure 1).
Gut microbiota releases metabolic products, which can affect
intestinal integrity and stimulate the production of cytokines with
pro-inflammatory or anti-inflammatory activity (Hooper et al.,
2012) and provides numerous nutritional benefits to the host,
including vitamins and short chain-fatty acids (SCFAs). SCFAs
are bacterial fermentation products that act by modulation of
IECs and leukocyte development (Corrêa-Oliveira et al., 2016).
Clostridial species are the major producer of SCFAs, and this is
probably associated with their potent anti-inflammatory activity
in experimental models. An anti-inflammatory role has been
associated with members of the genus Lactobacillus that are
poor producers of SCFAs but strong producers of lactic acid
that, in turn, can be rapidly converted to butyrate (one of the
most important SCFA) by other members of the microbiota
(Wullt et al., 2007).
Also, bacteriophages play an important role in promoting
the development and activity of the immune system through
interactions with their host bacteria. They act as reservoir
of genetic diversity, being vehicles for the genetic exchange
among bacteria. Indeed, phages are carriers of virulence
determinants, resistance genes, and metabolic pathways through
the process of genetic transduction, with a consequent impact
on host metabolism and immunity (Duerkop and Hooper, 2013;
Chatterjee and Duerkop, 2018). Qualitative and quantitative
alterations in the community of bacteriophages associated with
the gut mucosa can influence the bacterial microbiota ecology
and pathogen fitness; this could have profound effects on
modulation of pro-inflammatory or anti-inflammatory responses
(Zuo and Ng, 2018).
The crosstalk between the microbiota and the immune
system takes place throughout the course of life and is
influenced by different immune responsiveness at the extremes
of age. Indeed, the immune system of elderly people is
remodeled with fewer naïve cells, mainly owing to changes
in progenitor cells and primary lymphoid organ involution,
increase in dysfunctional memory cells, and altered innate
immune response (Linton and Dorshkind, 2004; Pawelec, 2018),
leading to greater susceptibility to infectious diseases and reduced
responses to vaccination (Ciabattini et al., 2018a). At the same
time, the immune system of elderly people is characterized
by the progressive onset of a chronic, sterile, and low-grade
inflammation, a set of phenomena described by the concept
of inflammaging (Franceschi et al., 2000). In correlation with
these phenomena of immunosenescence and inflammaging, a
profound remodeling of gut microbiota occurs progressively with
age (Biagi et al., 2013; Odamaki et al., 2016). Deterioration
of physiological functions of the human body can contribute
to the reduction of species such as Bifidobacteria in the gut
microbiota, whereas inflammation may both induce an increase
of facultative aerobes (i.e., Enterobacteriaceae, Enterococcaceae,
and Staphylococcaceae, which can grow in an inflamed gut
because they are relatively oxygen tolerant) and inactivate
the strict anaerobic Firmicutes. Moreover, Enterobacteriaceae
have the capability to secrete LPSs, which may act as an
endotoxin, increasing inflammation in the gut (Rhee, 2014;
Kumar et al., 2016).
In general, a reduced biodiversity and compromised
stability of the intestinal microbiota with respect to younger
individuals have often been reported in the elderly people,
even if a large inter-individual variability in older subjects
has been observed (Claesson et al., 2011). Moreover, the
comparison of studies performed in subjects having different
nationalities highlighted a certain country specificity in
how the aging process impacts on the intestinal microbiota
(Biagi et al., 2013), possibly related to differences in lifestyle
and dietary habits.
In summary, the microbiota plays a key role in the
development and modulation of the immune system
throughout the life, and at the same time the immune
system contributes to maintain microbial homeostasis; this
interplay can be one of the factors that impact vaccine
responses. Furthermore, the association between certain
members of the microbiota and activation of specific arms
of intestinal immunity, linked to lifestyle geographic and
environmental factors, can play a critical role in the heterogeneity
of disease prevalence and possibly in vaccine responses
throughout the world.
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FIGURE 2 | Factors affecting the immune response to vaccination. Immune responses to vaccination are affected by factors related to the vaccine, the host immune
system, and the microbiota. The vaccine formulation (including the delivery system or adjuvant), the antigen dose, the route of vaccine administration (parenteral or
mucosal), and the prime-boost strategies selected for the vaccination schedules deeply influence the host immune response to vaccination. At the same time, the
host immune system is affected by age, genetic background, and possible disorders (allergy, autoimmunity, immunodeficiency, etc.). The host gut microbiota,
susceptible to age, nutritional and environmental factors, gender, hygiene conditions, antibiotic treatment, use of probiotic, or chronic infections, also impact the
capacity to respond to vaccination. Vaccination outcome is the result of the complex interplay of these different factors.
POTENTIAL ROLE OF THE MICROBIOTA
IN THE IMMUNE RESPONSE TO
VACCINATION
The mechanisms that can affect the response to vaccination
are complex and include factors related to the vaccine, the
host immune system, and the gut microbiota (Figure 2).
The characteristics of the vaccine, including the vaccine
formulation (i.e., vaccine delivery systems, adjuvants,
and immunomodulators), the antigen nature (i.e., whole
microorganism, purified protein, polysaccharide, and nucleic
acid), the dose, the route of immunization (parenteral
or mucosal), and vaccination schedule (homologous and
heterologous prime-boost strategies, intervals between doses,
etc.) are of critical importance for shaping the host immune
response and eliciting the optimal response for a specific
pathogen (Harandi and Medaglini, 2010; Ciabattini et al.,
2013, 2015, 2016, 2018b; Fiorino et al., 2013; Cunningham
et al., 2016; Dacoba et al., 2017; Handel et al., 2018). Vaccine
immune response is also deeply affected by the host immune
system, especially at the extremes of life, when early life immune
immaturity or age-associated immune alteration is present
(Mohr and Siegrist, 2016; Ciabattini et al., 2018a). In the elderly,
the efficacy of vaccination is indeed strongly reduced than in
younger adults, mostly owing to alteration of their immune
system, where some immunological components decline whereas
others, such as inflammation, are increased (Ciabattini et al.,
2018a). Because the intestinal microbiota plays a crucial rule
in the regulation of the immune system, it can be considered
as another factor that might affect how individuals respond
to vaccinations (Zimmermann and Curtis, 2018b). Microbial
community composition is in turn affected by age, environmental
and socio-economic factors, diet, gender, chronic infections,
immunosuppressive chemotherapy, antibiotic treatment, or
probiotic use (Conlon and Bird, 2014; Becattini et al., 2016;
Thursby and Juge, 2017; Vemuri et al., 2018; Zimmermann and
Curtis, 2018a; Figure 2). Variations in microbial communities,
due to environmental, socioeconomic, nutritional, and hygiene
conditions, could in part explain the geographical heterogeneity
in vaccine responses (Velasquez et al., 2018).
Even though the specific mechanisms by which the microbiota
affects vaccine responses are not completely understood, it has
been demonstrated that the microbiota constitutes a constant
source of natural adjuvants capable of activating a multitude
of pathways that control innate and adaptive immunity (Pabst
and Hornef, 2014). This “endogenous adjuvant potential” was
demonstrated in a study on inactivated influenza vaccine that
showed that GF or antibiotic-treated mice had significantly
impaired antibody responses to this vaccine (Nakaya et al., 2011;
Oh et al., 2014). The study demonstrated a strong correlation
between the expression of TLR5 and the magnitude of the
antibody response, which was significantly reduced in TLR5-
deficient mice immunized with TIV than in wild-type mice. By
using GF mice and antibiotics treatment, it was demonstrated
that commensal bacteria were the source of TLR5 ligands
responsible for the enhancement of immune response to TIV.
Oral reconstitution with a flagellated strain of Escherichia coli
was sufficient to restore the normal antibody response. Similar
Frontiers in Microbiology | www.frontiersin.org 6 July 2019 | Volume 10 | Article 1305
fmicb-10-01305 July 1, 2019 Time: 17:2 # 7
Ciabattini et al. Microbiota and Vaccines
results were observed also toward the inactivated poliovirus
vaccine (Oh et al., 2014), but not toward other vaccines such
as adjuvanted vaccine against tetanus–diphtheria–pertussis or
a live-attenuated yellow fever vaccine (YF-17D), demonstrating
that many factors, such as vaccine formulation components and
route of immunization, influence the relation between microbiota
and immune response (Oh et al., 2014).
Besides flagellin, other components of the microbiota have
shown an adjuvant role in the induction of the immune
response to vaccination. The peptidoglycan component muramyl
dipeptide (MDP), agonists of nucleotide-binding oligomerization
domain containing 2 (Nod2) sensor, has been shown to enhance
the adjuvanticity of cholera toxin in the nasal cavity of mice (Kim
et al., 2016). The depletion of bacteria by antibiotic treatment
suppressed the induction of the humoral response following
mucosal immunization, whereas reconstitution of GF mice with
a Nod2 agonist promoted robust CT adjuvant activity, thus
confirming that the microbiota influences mucosal adjuvant
activity (Kim et al., 2016). Similarly, the use of monophosphoryl
lipid A (MPL), a component of bacterial LPS recognized by
the TLR4, enhanced the adaptive responses during vaccination
(Duthie et al., 2011).
It has recently been shown that antibiotic-driven dysbiosis in
early life of mice leads to impaired antibody responses to five
different adjuvanted and live vaccines frequently administered
to infants worldwide including the meningococcal serogroup
B vaccine (Bexsero); the meningococcal serogroup C vaccine
(NeisVac-C); the 13-valent pneumococcal conjugate vaccine
(Prevenar); the hexavalent combination vaccine against hepatitis
B, diphtheria, tetanus, pertussis, Haemophilus influenzae type
b, poliomyelitis virus (INFANRIX Hexa); and the tuberculosis
BCG vaccine (Lynn et al., 2018). In all cases, early exposure
to antibiotics resulted in impaired antibody responses, while
T-cell cytokine production was not reduced. Restoration of the
commensal microbiota following antibiotic exposure rescued
these impaired responses. In contrast, antibiotic-treated adult
mice did not exhibit impaired antibody responses to vaccination.
Therefore, the impairment of humoral responses seemed to be
dependent on antibiotic-driven dysbiosis rather than on direct
effects of the antibiotics themselves.
Clinical trials exploring the association of the gut microbiota
with vaccine response in humans or comparing the fecal
microbiota composition and diversity of responders to non-
responders have been performed in high- and low-income
countries across diverse ages. The potential impact of the
gut microbiota has been investigated with systemic vaccines
(Huda et al., 2014), but mostly with oral vaccines, such
as oral RVV, oral polio vaccine (OPV), and cholera in
infants/children living in low-income countries (Levine, 2010;
Magwira and Taylor, 2018). The comparison of the pre-
vaccination fecal microbiome composition of RVV responders
and non-responders in Ghanaian and Pakistani infants supported
a correlation between microbiome composition and RVV
immunogenicity (Harris et al., 2017; Harris V. et al., 2018).
Bacteria related to Streptococcus bovis species were more
abundant in Ghanaian responders than in non-responders,
resulting in a significant positive association with RVV efficacy,
whereas Bacteroides and Prevotella species, more represented
in the microbiome of non-responders correlated with a lack
of RVV response (Harris et al., 2017). Similarly, in Pakistani
infants, RVV response positively correlated with increased
ratio of Gram-negative over Gram-positive bacteria, notably
reflected in an approximately three-fold increased abundance
of the Proteobacteria related to Serratia and E. coli (Harris
V. et al., 2018). The intestinal microbiota of matched Dutch
infants, with high RVV immune responses, showed also a higher
abundance of Proteobacteria, particularly Gammaproteobacteria,
which include bacteria related to Serratia and E. coli. Gram-
negative bacteria, such as Proteobacteria, can stimulate innate
immune responses, such as through their expression of
flagella or toxigenic LPS. Proteobacteria or their cell envelope
components may therefore be acting as natural immune
adjuvants in the Pakistani infant population. These studies
provide relevant insights to deepen the causative association
between microbiome composition and RVV immunogenicity,
and offer a model for studying how the immunogenic potential
of the microbiota could be exploited to improve vaccine
immunogenicity (Harris, 2018). The modulation of the resident
microbial community through the treatment with antibiotics
has also been investigated as possible strategy to increase RVV
immunogenicity (Harris V.C. et al., 2018).
Supplementation with probiotics is another strategy assessed
for improving vaccine immunogenicity by modulating
the resident microbiota. Probiotics are defined as live
microorganisms, which are beneficial to the host when
administered orally in adequate amounts (thought to be
≥109 colony-forming units daily) (Hill et al., 2014). The
most frequently used microorganisms are Lactobacillus spp.,
Bifidobacterium spp., and Saccharomyces boulardii. Recently,
two systematic reviews have extensively analyzed the possible
influence of probiotics on oral (Church et al., 2019) or both
oral and parenteral (Zimmermann and Curtis, 2018a) vaccine
responses. A total of 26 studies investigating the use of 40
different probiotic strains on the efficacy of 17 different vaccines
(DTP, DTwP, DTaP-Hib, DTaP-IPV-Hib, HAV, HBV, Hib,
LAIV, MMRV, OCV, OPV, ORV, PCV7, PPV23, polio, TIV, and
Ty21a) were reviewed (Zimmermann and Curtis, 2018a). The
meta-analysis concluded that a beneficial effect of probiotics
was reported in about half of the studies, and it was strongest
for oral vaccinations and for parenteral influenza vaccination,
suggesting a possible beneficial role in elderly people, in whom
it is known that seroconversion rates to influenza vaccination
are lower than in younger people. No significant benefits on the
immune response to oral vaccination were instead reported in
the analysis performed by Church, who analyzed a total of four
oral studies (Church et al., 2019). Further studies are needed
to fully elucidate the role of probiotics on modulating vaccine
immune responses, and specific focus should be on establishing
optimal strains, doses, and timing of administration.
The impact of environmental enteropathy (Gilmartin and
Petri, 2015)—a microbiota alteration associated with chronic
intestinal inflammation due to the increased exposure of infants
living in resource-poor settings to fecal–oral bacteria through
contaminated water and food—has also been investigated in oral
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vaccination (Kirkpatrick et al., 2015; Parker et al., 2018). No
inhibitory effect of enteropathogens on vaccine response was
reported, even though the differences in the methodologies used
for microbiome analysis with respect to those of other studies
can impact the results observed. Also, the small bowel bacterial
overgrowth (SBBO) elicited by the presence in the small bowel
of fecal bacterial species usually restricted to the large bowel
has been investigated as a possible factor that impaired vaccine
response to cholera vaccine CVD 103-HgR (Lagos et al., 1999).
The hypothesis is that live oral vaccines might be destroyed by an
already activated innate system with consequently poor induction
of specific immune responses by antigens enclosed in the vaccines
(Levine, 2010).
The potential role of the microbiota on the immune
response to parenteral vaccination has been investigated
in Bangladeshi infants (Huda et al., 2014). Actinobacteria
were the most abundant phylum recovered, followed by
Firmicutes, Proteobacteria, and Bacteroidetes. Within the
phylum of Actinobacteria, the most abundant genera were
Bifidobacterium, and the subspecies Bifidobacterium infant
predominated. A positive association between Bifidobacterium
and some adaptive immunological responses was observed,
such as CD4+ and CD8+ T-cell proliferative responses to PPD
and TT, the delayed-type hypersensitivity to PPD, and specific
IgG responses to TT and hepatitis B (HBV) vaccines, whereas
high levels of enteric pathogens such as Enterobacteriales and
Pseudomonadales were associated with neutrophilia and lower
vaccine responses (Huda et al., 2014).
A summary of the different pre-clinical and clinical studies
performed for dissecting the intersection between intestinal
microbiota and vaccine response is reported in Table 1.
An important technical challenge when studying the role of
microbiota on the immune response to vaccines is related to
the methods used for identifying fecal or intestinal microbial
composition. Recently, bioinformatics approaches and high-
throughput bacterial genome sequencing have significantly
improved our knowledge of the role of the microbiota in health
and disease, as described in the next paragraph. In-depth analysis
of the impact of the microbiota on vaccine responses in humans,
using the latest technologies, is instrumental for identifying
strategies to improve vaccine efficacy and duration of protection.
NEW TOOLS TO STUDY THE IMPACT OF
THE MICROBIOME ON THE IMMUNE
RESPONSE TO VACCINATION
The influence of gut microbiota on vaccine immune responses
can be evaluated by an integrated approach between microbiome
characterization and vaccine immune response through a systems
biology approach. The availability of novel tools to deeply analyze
the microbiome, such as next-generation sequencing (NGS)
technologies, and the host immune response are paving the way
for elucidating the impact of the microbiome in modulating the
vaccine immune response (Figure 3).
Recently, NGS technologies such as Illumina, Ion Torrent
(Life Technologies), Pacific Biosciences, Nanopore Sequencing
(Oxford Nanopore Technologies), and the bioinformatics tools
developed to interpret sequence data have revolutionized the
characterization of microbial communities, overcoming some
limitations of the culture-based methods leading to an improved
and deeper understanding of the microbial population within
an ecosystem. Sequence-based methods provide information for
identifying microorganisms and outlining their physiological
functionality, whereas classical culturing techniques are limited
to the study of phenotypic characteristics.
NGS approaches include 16S rRNA gene sequencing,
metagenomics, and metatranscriptomics. The majority of
microbiome studies characterize bacteria present in a sample
by sequencing a fragment of the 16S rRNA encoding gene,
a process called metataxonomics (Marchesi and Ravel, 2015).
The 16S rRNA gene has the advantage of containing highly
conserved regions whose sequence is conserved in most bacterial
species and nine hypervariable regions (V1–V9) whose sequence
is specific for a given species. Deep sequencing of these
hypervariable regions is used to define the composition of
bacterial communities and to compare communities over time
or across variable conditions such as antibiotic treatments (Faust
and Raes, 2012). Long-read sequencing of the 16S rRNA gene
is a promising approach to provide high-resolution analysis of
microbial communities at the species level, too. Metataxonomics
represents a powerful tool for the analysis of the microbiota,
improving taxonomy resolution to the strain level.
Whereas the marker gene-specific approach allows for the
investigation of microbial diversity in an environment by a
common marker gene set, whole-genome sequencing (WGS)
provides sequencing of genomic DNA extracted from the entire
microbial community to catalog all the genetic materials present
in a sample. This approach allows for a global picture of
microbial population, producing an unbiased representation
of the complete set of microbial genes (Sharpton, 2014;
Aguiar-Pulido et al., 2016).
DNA-sequencing-based approaches cannot generally
distinguish between living and metabolically active, damaged,
or dead bacterial cells, or free DNA, providing a partial vision
of the functional profile of a microbial community. RNA
sequencing analyses can identify living and metabolically active
cells, informing on transcriptional activity of the community.
Knowledge of the transcriptome of a given organism offers
significant insights into cellular processes and allows the
identification of proteins that may not be produced or expressed
under current culture assay conditions.
The development of new “omics”-based technologies has
made possible to rapidly investigate the diversity of microbial
populations and at the same time to characterize the relative
abundance of all taxa and functions in a defined community
(Jansson et al., 2012). As for metagenomics, it is now
possible to perform whole transcriptome shotgun sequencing.
Metatranscriptomics, in fact, involves the complete sequencing of
the transcriptome (coding and non-coding RNAs) and provides
a deeper understanding of the functional output of the genome
and valuable insight into gene expression patterns, gene function,
and regulation (van Vliet, 2010; Gilbert and Hughes, 2011).
Combined approaches that provide information on both identity
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FIGURE 3 | Integrated approach for analyzing the relationship between microbiota and immune response following vaccination. A deep characterization of the gut
microbiome can be obtained by NGS approaches, including metataxonomics, metagenomics, metatranscriptomics, and metabolomics. Advanced technologies,
including multiparametric flow cytometry and transcriptomic analysis, allow to profile both the humoral and cellular immune responses. A systems biology integration
of microbiome characterization with host response analysis upon vaccine administration could allow to better correlate the influence of the intestinal microbiome on
vaccine responses.
and physiology of the bacteria in a community can improve the
characterization of the microbiome.
In this view, metabolomics provides identification and
quantification of all metabolites (small molecules released by
the organism into the immediate environment) produced by
a microorganism or collectively by a microbial community of
a sample. The metabolome (the set of all metabolites present
in any given strain or microbial community) represents an
important evidence of community function and is considered
the most direct indicator of the homeostasis alteration in a
specific environment (such as dysbiosis). Metabolomics studies
the consequences of the shifts in the collective gene expression
of the microbial community that modifies the medium where
the microbial community must feed, grow, reproduce, and
cooperate or compete to survive (Aguiar-Pulido et al., 2016). The
most common platforms used to characterize the metabolome
are nuclear magnetic resonance (NMR) spectroscopy and mass
spectrometry (MS) linked to a liquid chromatography separation
system (Jansson et al., 2012). The application of these approaches
can revolutionize the study of complex interactions between the
microbiota and the immune system.
At the same time, the advancement of multiple technological
platforms to examine the host immune response has allowed
to profile the humoral and cellular immune responses
to vaccination. Promising approaches used to measure
immunity induced following vaccination include antibody-
profiling technologies, high-throughput flow cytometry,
transcriptomic analysis (Furman and Davis, 2015). Novel
analytical approaches, able to integrate diverse facets of the
humoral immune response and define the relationships between
antibody populations and functions, are now available. These
approaches reveal features of vaccine-induced “fingerprints”
and offer new insights concerning polyclonal antibody
immune responses elicited by vaccines (Chung et al., 2015;
Kawahara et al., 2019).
Measure of the frequency and functions of antigen-specific
lymphocytes can be obtained by multiparametric flow cytometry
employing antibody panels covering the simultaneous analysis
of cell surface markers, multiple cytokines, and other functional
markers. High-throughput flow cytometry allows to dissect
both B and T immune responses. For example, antigen-specific
CD4+ T lymphocytes, which play a fundamental role in the
adaptive immune response upon vaccination, can be detected
and characterized by MHC class II–peptide complex tetramers
(Crawford et al., 1998; Prota et al., 2015) and their effector
function, that is, cytokine production, can be assessed (Huang
et al., 2013; Pastore et al., unpublished). Novel computational
techniques have been developed in the recent years for analyzing,
visualizing, and interpreting large amounts of data obtained by
multiparametric flow cytometry (Saeys et al., 2016) and can be
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employed, for example, for better visualizing polyfunctional T
cells elicited by vaccination (Ciabattini et al., 2018b).
Nucleic acid sequencing enables a very broad approach
to immunoglobulin or TCR repertoire analysis, allowing
the determination of the diversity and clonal expansion of
lymphocytes responding to vaccine (Galson et al., 2014; VanDuijn
et al., 2017). The NGS methodology has become a core
technology in vaccine analysis (Dhiman et al., 2009; Santoro
et al., 2018) and, integrated with immunological results, has
been used to profile the human response to different vaccines.
This integrating approach is called “systems biology” and can be
used to analyze multiple data types related to complex biological
interactions by using computational analysis and mathematical
modeling and to predict vaccine protection and immunogenicity
(Querec et al., 2009; Li et al., 2014; Nakaya et al., 2016; Kazmin
et al., 2017; van den Berg et al., 2017).
A systems biology integration of microbiome characterization
with host response analysis upon vaccine administration
could allow to better correlate the influence of the intestinal
microbiome with vaccination (Figure 3).
CHALLENGES IN THE STUDY OF THE
POTENTIAL ROLE OF THE MICROBIOTA
IN VACCINE IMMUNE RESPONSE
The characterization of the potential role of the microbiome
on vaccine immunogenicity might help in the tailoring of
vaccination strategies; nevertheless, there are some challenging
factors that need to be properly addressed.
The application of culture-independent techniques,
such as metagenomics and metatranscriptomics, have
expanded the experimental tools available for studying
the microbiome, providing information on the taxonomic
profile of a microbial community and contributing to the
characterization of the dynamics of functional profiles
with varying conditions (Aguiar-Pulido et al., 2016).
Furthermore, transcriptomic and metabolomic analysis of
the host responses can provide important insights on the
impact of microbial community on vaccine response. The
application of systems biology approaches offers important
opportunities to integrate data related to both microbiome
and the host vaccine response. A critical challenge remains
in the identification of microbiome targets correlating with
vaccine immunogenicity.
Another critical aspect is the availability of reliable animal
models with defined microbial composition to explore host–
microbe interactions. Gnotobiotic models, including GF, or
antibiotic-treated mice have provided substantial insights on
the interplay of the microbiota and host immune system
(Smith et al., 2007), identifying key microbes responsible for
the development of the intestinal immune system (Umesaki
and Setoyama, 2000), and have the potential to tell us much
about the impact of the microbiota on the vaccine responses
(Fiebiger et al., 2016; Cram et al., 2018). However, the absence
of microbiota in GF mice or the reduced microbial richness
and diversity in mouse models with a defined microbiota does
not fully represent the complex interactions that occur within
the microbiota of conventionally raised mice; therefore, results
from gnotobiotic mice should be interpreted with caution.
Moreover, the murine microbiota is influenced by various factors
such as breeding environment, interchange variability, genetic
backgrounds, diet, sex, and age (Nguyen et al., 2015; Miyoshi
et al., 2018). To minimize these effects and improve consistency
and reproducibility in murine microbiota studies, procedures
such as using a single genetically identical strain, housing all
animals in one specific room (to control environment), using the
same diet, and utilizing age- and sex-matched mice should be
employed (Miyoshi et al., 2018).
In human studies, the large inter-individual variability of the
microbiota together with the genetic diversity is a confounding
factor that is challenging to overcome when studying host–
microbe interactions. Several studies that aimed to assess
the impact of the microbiome in vaccine response have
been conducted in geographically different populations with
different microbiome compositions, as performed in low- and
high-income countries (Harris et al., 2017; Harris V. et al.,
2018). Another approach is based on altering the microbiota
composition with antibiotic treatment to promote amplification
or reduction of specific bacterial species prior to vaccine
administration (Harris V.C. et al., 2018). This model could be
highly informative even if limitations such as the off-target effects
of antibiotics and their possible impact on immune responses as
well as the impact of the antibiotic spectrum could influence the
study readouts (Harris V.C. et al., 2018).
Furthermore, the majority of vaccinations are given during
the first few years of life when human immune response and
the microbial community develop in concert and are reciprocally
influenced. Therefore, careful attention should be given to
understanding how the early microbiome affects vaccination
and how vaccination may influence the development of the
microbiota itself (Jamieson, 2015). Moreover, since there are
significant differences in the intestinal microbiota in infants
or children compared with adults (Yatsunenko et al., 2012),
studies of microbiota and vaccine immune response should be
performed in different age groups, even though infant studies are
more challenging.
An additional bottleneck is that currently most of the clinical
studies performed can only assign correlations but not causality,
and the correlations have been made with immunogenicity and
not vaccine efficacy (Harris, 2018).
CONCLUSIONS
Vaccine efficacy is based on the capacity of the antigen to
elicit a protective immune response and on the immune
system competence to respond appropriately to an antigenic
stimulation. Recent studies suggest that the microbiota could
represent a key element potentially capable to affect both
these functions by acting as immunologic modulator as well
as natural vaccine adjuvant. The mechanisms underlying the
crosstalk between the gut microbiota and immune system are
of critical importance especially in early life when the majority
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of vaccinations are given. During the first years of life, the
early gut microbiota can shape immunologic functions and
vice versa owing to both the plasticity of the immune system
and at the same time the instability of the microbiota. This
interaction, together with other genetic and environmental
factors, results in a defined microbiota composition and
richness that can diversify the individual response to
vaccinations. Variations in microbial communities may in
part explain the geographical heterogeneity in vaccination
success, and a deep understanding of these dynamics could
provide a tool to improve immunization strategies. There
are evidences of the low response to oral vaccines in low-
income countries, and it has been supposed that differences in
the intestinal microbiota composition due to environmental,
socioeconomic, nutritional, and hygiene conditions could
justify these discrepancies. These findings make it reasonable
to speculate a hypothetical role of the microbiota in vaccine
non-responders. To date, few studies analyze the mechanism
by which the microbiota influences the immunogenicity of
vaccines, and the results do not show a direct causal link
between specific community composition and responsiveness.
But interestingly, some bacterial species or their specific
components emerge as potent modulators of humoral or
cellular immunity among vaccine responder subjects. In this
context, different approaches are used to test the potential
adjuvant effect of certain probiotic strains to enhance immune
response to both oral and parenteral vaccines with discordant
results. Although these studies suggest an important role
of the microbiota in the modulation of vaccine immune
responses, there is the need for further investigations to
clearly demonstrate this intersection. The availability of
advanced technologies for characterizing both the microbial
community and the immunological responses integrated trough
a systems biology approach offers the opportunity to deeply
analyze the interplay of the microbiota with the immune
response to vaccination.
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